Effect of FLM on CA1 pyramidal cell mIPSCs
| Group | mIPSCs | Group | Zolpidem Potentiation | ||
|---|---|---|---|---|---|
| Amplitude | τ | Amplitude | τ | ||
| pA | ms | % | |||
| CON-VEH (n = 12/9) | −21.1 ± 3.2 | 23.4 ± 1.9 | CON-VEH (n = 7/6) | 121.1 ± 10.1 | 152.1 ± 14.5 |
| CON-FLM (n = 10/6) | −21.7 ± 4.8 | 22.2 ± 1.1 | CON-FLM (n = 7/5) | 168.4 ± 28.3 | 147.4 ± 14.6 |
| pvalue | .89 | .59 | .11 | .81 | |
| FZP-VEH (n = 10/7) | −10.8 ± 1.9 | 27.6 ± 1.1 | FZP-VEH (n = 6/5) | 129.1 ± 7.5 | 111.3 ± 6.2 |
| p value vs. CON-VEH | .01* | .11 | .48 | .02* | |
| FZP-FLM (n = 15/9) | −18.8 ± 1.9 | 22.9 ± 1.8 | FZP-FLM (n = 6/5) | 117.5 ± 14.0 | 158.8 ± 15.7 |
| p value vs. CON-FLM | .45 | .65 | .12 | .57 | |
Values are means ± S.E. n = cells/rats. FLM: i.p. injection of FLM; VEH: i.p. injection of FLM vehicle. Zolpidem potentiation (%) is expressed as a percentage of the baseline value in the absence of zolpidem. *, significant difference (p ≤ .05) between 1-week FZP- and saccharin-treated control (CON) groups. p values are versus control of respective group.